Brain HealthAzetukalner Cuts Seizures Up to 53% in Drug-Resistant Focal Epilepsy in Phase 3 Trial
About half of people with epilepsy do not achieve long-term seizure freedom with their first medication. This phase 3 trial tested azetukalner, a new drug that opens potassium channels to calm overactive brain cells. It enrolled 374 adults who were still having at least 4 focal seizures a month on 1 to 3 other medications. Over 12 weeks, median seizure frequency fell 10% on placebo, 35% on 15 mg and 53% on 25 mg. More than half of those on 25 mg had at least a 50% drop in seizures, versus about 1 in 5 on placebo. Dizziness, sleepiness, tremor and confusion were the main side effects, and they were more frequent at the higher dose. About 15% of those on 25 mg stopped the drug because of side effects. No deaths occurred.